share_log

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K：重大事件
美股SEC公告 ·  10/25 17:03

Moomoo AI 已提取核心訊息

Mangoceuticals, Inc., a Texas-based pharmaceutical company, has reported the sale of equity securities in a recent filing with the SEC. On October 24, 2024, the company issued an Advance Notice to Platinum Point Capital, selling 33,333 shares of common stock at $2.36 per share, resulting in net proceeds of $78,787 after fees and expenses. This transaction is part of an Equity Purchase Agreement (ELOC) that allows the company to direct the purchaser to buy up to $25 million of its common stock. The shares were sold at 90% of the gross proceeds from their resale over a three-day valuation period. Additionally, on October 18, 2024, the conversion of 200 shares of Series B Preferred Stock into 93,299 shares of common stock took place at a value of $2.358 per share, totaling $220,000. Both the resale of the common stock and the conversion of the Series B Preferred Stock have been registered under the Securities Act, with the company claiming exemptions from registration for these issuances.
Mangoceuticals, Inc., a Texas-based pharmaceutical company, has reported the sale of equity securities in a recent filing with the SEC. On October 24, 2024, the company issued an Advance Notice to Platinum Point Capital, selling 33,333 shares of common stock at $2.36 per share, resulting in net proceeds of $78,787 after fees and expenses. This transaction is part of an Equity Purchase Agreement (ELOC) that allows the company to direct the purchaser to buy up to $25 million of its common stock. The shares were sold at 90% of the gross proceeds from their resale over a three-day valuation period. Additionally, on October 18, 2024, the conversion of 200 shares of Series B Preferred Stock into 93,299 shares of common stock took place at a value of $2.358 per share, totaling $220,000. Both the resale of the common stock and the conversion of the Series B Preferred Stock have been registered under the Securities Act, with the company claiming exemptions from registration for these issuances.
總部設在德克薩斯州的藥品公司Mangoceuticals報告稱，該公司在最近向SEC提交的文件中報告了股權證券的出售。2024年10月24日，該公司向鉑金創投發出了預售通知，以每股2.36美元的價格出售33,333股普通股，經過費用和開支後淨收益爲78,787美元。此交易是資產購買協議（ELOC）的一部分，允許該公司指導購買者買入其多達2500萬美元的普通股。這些股份以其在參考期爲3天內重新銷售的總收益的90%出售。此外，2024年10月18日，200股B系列優先股轉換爲93,299股普通股，每股轉換價格爲2.358美元，總價值爲220,000美元。這些普通股的再銷售以及B系列優先股的轉換均已根據證券法進行了註冊，公司聲稱對這些發行準備了登記豁免。
總部設在德克薩斯州的藥品公司Mangoceuticals報告稱，該公司在最近向SEC提交的文件中報告了股權證券的出售。2024年10月24日，該公司向鉑金創投發出了預售通知，以每股2.36美元的價格出售33,333股普通股，經過費用和開支後淨收益爲78,787美元。此交易是資產購買協議（ELOC）的一部分，允許該公司指導購買者買入其多達2500萬美元的普通股。這些股份以其在參考期爲3天內重新銷售的總收益的90%出售。此外，2024年10月18日，200股B系列優先股轉換爲93,299股普通股，每股轉換價格爲2.358美元，總價值爲220,000美元。這些普通股的再銷售以及B系列優先股的轉換均已根據證券法進行了註冊，公司聲稱對這些發行準備了登記豁免。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間